Johnson & Johnson Beats Estimates, Shares Surge
Johnson & Johnson posted higher first-quarter earnings on Tuesday as aggressive cost cutting helped offset plunging sales of anemia drugs hit by safety concerns and medicines facing generic competition.
Add to My Watchlist
What is My Watchlist?